750 studies found for:    Erlotinib
Show Display Options
Rank Status Study
1 Active, not recruiting Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma
Condition: Head and Neck Squamous Cell Carcinoma
Interventions: Drug: Erlotinib;   Drug: Erlotinib plus sulindac;   Drug: Placebo
2 Terminated Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
Condition: Ependymoma
Intervention: Drug: Erlotinib
3 Terminated
Has Results
Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer
Condition: Breast Cancer
Interventions: Drug: erlotinib hydrochloride;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: biopsy;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy
4 Recruiting Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib
Condition: Non Small Cell Lung Cancer
Intervention: Drug: BKM120 and Erlotinib
5 Completed Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib
Condition: Lung Adenocarcinoma
Intervention: Drug: erlotinib along with cetuximab
6 Active, not recruiting
Has Results
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: Erlotinib hydrochloride
7 Completed A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)
Condition: Lung Cancer
Interventions: Drug: Erlotinib;   Drug: Satraplatin
8 Active, not recruiting Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Condition: Non-Small Cell Lung Cancer (NSCLC) With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy
Interventions: Drug: OSI-906;   Drug: erlotinib;   Drug: placebo
9 Not yet recruiting A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline
Conditions: Non-small Cell Lung Cancer;   Advanced Solid Malignancies
Interventions: Drug: Theophylline;   Drug: Erlotinib
10 Completed
Has Results
Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Erlotinib + Sorafenib;   Drug: Erlotinib + Placebo
11 Active, not recruiting Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pazopanib;   Drug: Erlotinib
12 Withdrawn OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas
Condition: Pancreatic Cancer, Metastatic
Interventions: Drug: Gemcitabine, Erlotinib, OSI-906;   Drug: Gemcitabine, Erlotinib
13 Completed
Has Results
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Bevacizumab and Erlotinib
14 Active, not recruiting Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Erlotinib;   Drug: Hydroxychloroquine
15 Completed
Has Results
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pralatrexate Injection;   Drug: Erlotinib;   Dietary Supplement: Vitamin B12;   Dietary Supplement: Folic Acid
16 Completed A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Condition: Non Small Cell Lung Cancer
Interventions: Drug: ARQ 197;   Drug: Erlotinib;   Drug: Placebo
17 Recruiting Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer
Condition: EGFR-Mutant Lung Cancer
Intervention: Drug: erlotinib
18 Completed Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)
Conditions: Primary Sclerosing Cholangitis;   Trisomy 7;   Cholangiocarcinoma;   Chemoprevention
Intervention: Drug: Erlotinib (Tarceva)
19 Terminated Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib
Condition: Lung Cancer
Intervention: Drug: erlotinib
20 Active, not recruiting MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer
Conditions: Pancreatic Cancer;   Pancreatic Adenocarcinoma
Interventions: Drug: MK-0646;   Drug: Gemcitabine;   Drug: Erlotinib

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years